Company ProfilePremium

Hony Media Group

Company Profile Analysis

Ticker: 0419.HK弘毅文化集團

ESOMAR 23 Corporate BadgeISO Certifications Badge
Hony Media Group - Company showcase

Year Founded & Workforce

2002

114 Employees

Hony Media Group logo

Hony Media Group Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Hony Media Group Overview

Hony Media Group is a Hong Kong-listed, Cayman-incorporated micro-cap whose name has repeatedly lagged its business. Despite carrying "Media" in its name, essentially 100% of continuing revenue now comes from Echartnow (醫智諾), a Suzhou-based digitised-operations and compliant-marketing service provider to Chinese pharmaceutical companies (449 pharma clients and ~90,000 verified physicians). The entertainment franchise survives mainly as a 30.77% equity-accounted stake in South Korean drama producer HB Entertainment. In January 2026 the group sold its loss-making Meerkat Health pharma-wholesale platform for HK$1. Since June 2026 it has undergone a governance reset — Hony Capital's Zhao John Huan resigned as chairman, Tencent exited its stake, and long-time controlling figure Yuen Hoi Po returned as CEO — and pivoted toward a robotics operations platform (AIROBO) for China's property-management sector, backed by a 70%-owned JV. The company is loss-making, thinly capitalised and dependent on equity raises.


Company's own description (FY2025 Annual Report and 2026 Interim)

In its FY2025 Annual Report the Group described itself as principally engaged in three operating segments: (i) digitised operation services in the healthcare industry (Echartnow); (ii) a smart healthcare services platform (Meerkat Health); and (iii) entertainment and media. Following the January 2026 disposal of Meerkat Health, the 2026 interim results describe two continuing segments — Echartnow and Entertainment & Media — with Meerkat Health presented as a discontinued operation. The chairman's statement in the FY2025 AR framed the corporate vision around "AI + content", positioning the group to build a global platform for high-quality content creation, while Echartnow was described as "China's leading digital operations service provider for the pharmaceutical industry." From August 2026 the company added a third line — robotics platform operations via AIROBO (HK) Limited — and proposed renaming itself after that business.

Business model and revenue model

Echartnow (≈100% of continuing revenue, H1 2026). Echartnow earns information-technology service fees, consulting service fees and promotion service fees from pharmaceutical companies. Its revenue base is digitised marketing services: market research and site visits; execution of academic conferences, multidisciplinary-team (MDT) meetings and expert lectures (including live streaming and video editing); production and promotion of medical science-popularisation content (advertorials, short video, live broadcast); private- and public-domain precision promotion; and "doctor IP" brand-building for physicians. Higher-value services now include medical research support, real-world study (RWS) design, compliance-control tooling and AI-enabled patient-screening. The model is project/service-fee based (not subscription), with significant pass-through marketing cost (FY2025 gross margin 34.3%).

Entertainment & Media. No consolidated revenue in H1 2026 (FY2025: HK$0.23M). Economic exposure is via equity-accounted share of results of HB Entertainment (production of Korean TV dramas and films, and artist management).

Robotics platform operations (AIROBO, from Aug 2026). A hardware-agnostic "unified robotics operations platform" (AIROBO OS / AIROBO Platform 1.0) that connects multi-brand delivery, cleaning, inspection and security robots to property-management systems, elevators and access control. Revenue model not yet disclosed; co-build/co-operate agreements with property managers (5-year Longfor agreement; 3-year Greentown agreement) suggest platform/operations service fees. No revenue from this line had been reported as at 30 June 2026.

Discontinued: Meerkat Health. Originally a consumer smart-health platform (vaccines, health check-ups, private-domain e-commerce), it was pared back in 2024 to pharmaceutical wholesale only and sold on 30 January 2026.

Revenue mix by model (analyst characterisation, FY2025)

Revenue modelShare of FY2025 revenue (%)Basis
Services (Echartnow digitised operations)82.8HK$472.0M / HK$570.1M
Product trading (Meerkat pharma wholesale, now discontinued)17.2HK$97.9M / HK$570.1M
Licensing / IP products (Entertainment & Media)0.04HK$0.23M / HK$570.1M
Subscription0None disclosed

Value-chain position, customers and end-markets

Echartnow sits between pharmaceutical manufacturers (buyers) and physicians/patients (audience), functioning as an outsourced, compliance-wrapped digital commercial-operations vendor — analogous to a digital contract sales/marketing organisation. Customers are Chinese pharma companies; top-100 Chinese pharma accounted for 61% of Echartnow revenue in FY2025 (59% in FY2024). Named clients include Yiling Pharmaceutical, Qilu Pharmaceutical, CSPC Pharmaceutical Group, Jemincare and Innovent Biologics. Customer concentration is high: one customer ("Customer B") generated HK$92.7M, ~42% of H1 2026 revenue.

Independent characterisation

Hony Media is best understood as a restructuring micro-cap shell with one operating asset (Echartnow) and a newly grafted growth narrative (robotics). Corporate identity has shifted five times in roughly a decade (health/wellness → Huayi Tencent entertainment → internet healthcare → Hony "AI + culture" → AIROBO robotics). Each pivot has coincided with a change in sponsor. The 2026 sequence — Hony Capital chairman exits (June), Tencent sells out (August), robotics JV and name change announced within days, stock rises ~51% intraday on 7 August — is characteristic of narrative-driven re-rating in Hong Kong small caps. Echartnow, by contrast, is a real business: it turned to a segment profit (HK$3.3M) in H1 2026 after two years of cost restructuring, though on shrinking revenue.

Strategy

Stated strategy themes

"AI + content" (FY2025 AR, Chairman's Statement, March 2026): build a global platform for creating and producing high-quality content; candidate tracks include AI micro-dramas, AI comic-dramas, AI movies and content globalisation. The AR cited global micro-drama in-app purchase revenue of nearly US$2.8bn in 2025. Status: effectively shelved — the 2026 interim says management maintains a prudent attitude to Entertainment & Media other than holding the HB stake, and the Hony Capital chairman behind this vision resigned in June 2026.

  • Echartnow — "rooted in digital operations, winged by AI application scenarios": focus on Top-20 strategic clients with full-product-line access; replicate AI scenarios (chronic disease management, tumour follow-up); insurance collaborations on RWD; export the Shaanxi regional platform model; expand RWS and medical-data services ("Wei Jian Zhi Yan"); increase high-value project share; exit low value-added basic promotion.

Robotics platform operations (Aug 2026 onward): AIROBO as a neutral, multi-brand robot operations platform for property management; positioned as an "Android-like" OS layer between robot makers and buildings. Name change to AIROBO Platform Group signals this is now the core strategic narrative.

Initiatives in last 24 months

DateInitiativeDetail
Mar–Apr 2024Hony Capital partnershipHK$120M CB; Hony chairman installed; rename to Hony Media Group
2,024Meerkat Health streamliningExited vaccines, check-ups, private e-commerce
H1 2025Echartnow restructuringHeadcount and fixed-cost reduction; group headcount 221 → 127
2,025Echartnow standards leadershipLed drafting of "Compliance Development Guidelines for Biopharmaceutical Digitized Operations"; Shanghai Biomedical Digitized Operation Standard Innovation Consortium
Dec 202510:1 share consolidationRestores tradeable price
Jan 2026Meerkat Health disposalHK$1 consideration
Jan–Mar 2026CB maturity extensionTo 21 Apr 2028
May–Jul 2026Equity placementsHK$110M gross at HK$0.40; July proceeds earmarked for Echartnow AI platform and R&D
Aug 2026AIROBO JV and Platform 1.070/30 JV; Chengdu entity; property-manager agreements
Aug–Sep 2026Ecosystem buildingCo-founder of China Robot Industry Development Alliance; co-hosted robotics forum at Global Unicorn Summit (HK); CAS joint lab
Sep 2026Name change approvedAIROBO Platform Group Limited

ESG commitments: water-conservation targets integrated into ESG management; TCFD-style four-pillar climate disclosure; no quantified emissions-reduction target disclosed. Cost programmes: ongoing AI-tool adoption to cut admin costs (admin −46% YoY in H1 2026). Medium-term financial targets/guidance: none disclosed. Management expected Echartnow to "gradually recover and resume growth in 2026" (FY2025 AR) — H1 2026 revenue was still −9%, but segment profit turned positive.

Products & Services

Echartnow (醫智諾) — Digitised operation services in healthcare

OfferingDescription / capabilitiesTarget customerYear / statusPricing model
Echartnow platform (WeChat mini-app origin)Online ecosystem of ~90,000 real-name-verified physicians (end-2025, +48.9% YoY), covering paediatrics, oncology, cardiovascular etc.Pharma marketing & medical affairsLaunched 2021Not disclosed (service/promotion fees)
Digitised marketing servicesMarket research, site visits, campaign decision supportPharma brand teamsCore since 2021Project fees
Academic conference executionConference systems, MDT meetings, expert lectures, live streaming, video editingPharma medical/marketingCoreProject fees
Medical science popularisationAdvertorials, short video, live broadcasts for physician-led health educationPharma; physiciansCorePromotion fees
Precision promotionPrivate- and public-domain distribution of content (text, audio, video)PharmaCorePromotion fees
Doctor IP incubationBuilding physician personal brands; professional articles and videosPharma; KOL physiciansExpanding 2025—
High-value customised compliance marketing solutionsEnd-to-end compliance monitoring across business process; 36% of FY2025 Echartnow revenue, >50% in Q4 2025Top-tier & innovative pharma (e.g., Innovent)Scaled 2025Customised fees
Medical research support & Real-World Study (RWS) designStudy design, data supportInnovative drug companiesExpanding 2025–26—
"Intelligent Screening for Patient Recruitment: AI Intelligent Screening Platform"AI patient-screening for trial recruitment; listed on Suzhou AI Application Scenario Open ListPharma R&D2,025—
"Pharmaceutical Marketing Compliance and Precision Empowerment Platform"AI-enabled compliance control and precision marketing; on Suzhou AI listPharma commercial/compliance2,025—
"Comprehensive Medical Digital Empowerment Platform" (Shaanxi)Designation by Shaanxi Provincial Data and Government Services Bureau; regional medical-data platform modelLocal governments; pharma2,025—
"Wei Jian Zhi Yan" (衛健智研) RWD pilotReal-world-data application pilot converting medical data "resources to assets"Pharma, hospitals, clinical expertsLaunched H1 2026—
Medical Data + AI Professional Committee (Xi'an Data Industry Association)Echartnow serves as chairman unitIndustry ecosystemH1 2026—
Specialised pharmacy / e-prescription systemElectronic prescriptions and online paymentPharmacies, patientsDisclosed in ESG report—
Planned: "AI + chronic disease management", "AI + tumour follow-up"Roll-out to key customers nationwidePharmaPlanned (FY2025 AR)—
Planned: insurance collaborationsEfficacy evaluation & health management using RWDMedical/commercial insurersPlanned—

Certifications: GB/T 19001-2016 / ISO 9001:2015 quality management (FY2025 ESG Report).

AIROBO — Robotics platform operations (from Aug 2026)

OfferingDescription / capabilitiesTarget customerYear / statusPricing
AIROBO OS / AIROBO Robotics Operations Management Platform 1.0Hardware-agnostic unified access for heterogeneous robots; unified data model; spatial-semantic building model; task orchestration; integration with elevators, access control, property systems; dozens of mainstream robot models adaptedProperty-management companiesOfficially launched 28 Aug 2026; deployed in Greentown Services projects—
Longfor Property Robot Operations PlatformCo-built and co-operated platform; pilots at Huabei Yuhujing and Chengdu Xichen Yuanzhu (inspection & delivery robots)Longfor Property Services5-year agreement, 17 Aug 2026—
Greentown property robotics platformCo-built platformGreentown Service (2869.HK)3-year agreement, Aug 2026—
Robot service agreementRobot servicesA-Living (3319.HK)Sep 2026—
Robotics Operations Project LaboratoryJoint labInstitute of Mechanics, Chinese Academy of SciencesSep 2026—

Entertainment & Media (via HB Entertainment, 30.77% associate)

Title / assetTypeYearPerformance (Nielsen nationwide)
"Recipe for Love" (KBS 2TV)Weekend TV dramaJan 2026Average 14.5%, peak 18.0% (2026 Interim)
"Motel California" (MBC)TV dramaJan 2025Average 4.3%, peak 6.0% (FY2025 AR)
"Sky Castle"TV dramaBack catalogue—
"Partners for Justice" seriesTV dramaBack catalogue—
"My Love from the Star"TV dramaBack catalogue—
"Beautiful Love, Wonderful Life"TV drama2,019Topped national ratings (FY2019)
Artist management rosterLee Sung-min, Kim Yun-seok, Joo Sang-wook; Japanese actor Machida KeitaOngoing—
Historic film investments2015 film investment programme (~HK$369M); "Moonfall" (2022)Legacy—

Discontinued

Meerkat Health (獴哥健康): smart health services platform; vaccines, health check-ups and private e-commerce exited in 2024; pharma wholesale until sale on 30 Jan 2026.

  • Beijing Bayhood No.

Deep Sea Health stake (21.88%): held for sale; RMB23.2M disposal agreed.

Financial Narrative

Income statement

Notes: Operating loss is derived as gross profit + other income/gains − marketing & selling − R&D − administrative expenses (FY2025: 163.0 + 3.9 − 156.8 − 10.4 − 51.5). FY2022 loss before tax shown on restated basis (−317.0 as originally reported). EBITDA: not disclosed by the company; aggregator MarketInOut shows TTM EBITDA of approximately −HK$55.6M (Aug 2026). Revenue CAGR FY2021–FY2025: +15.2% (from a low base); FY2022–FY2025 (restated): −28.9% p.a.

Commentary. The five-year arc is a boom-and-bust in internet-healthcare revenue. Revenue jumped five-fold in FY2022 as Meerkat Health's trading revenue and Echartnow scaled, then contracted for three consecutive years. The FY2023 decline was Meerkat-driven (strategy change away from low-margin trading) while Echartnow grew 56%. FY2024 marked Echartnow's first decline (−8%) as pharma budgets tightened under China's anti-corruption campaign. FY2025 was the inflection: more than 60% of leading pharma companies suspended or cut non-core digital-marketing budgets in H1 2025, and Echartnow revenue halved — yet losses narrowed sharply because selling expense fell 56% and admin 27% after restructuring. Losses have never turned to profit in the period; cumulative net losses FY2021–FY2025 total about HK$837M against a market cap now under HK$800M.

Half-year trend (latest available)

Notes: H1 2025 revenue restated to continuing basis (Meerkat excluded). H1 2024 EPS is pre-consolidation; H1 2025/H1 2026 EPS reflect the 10:1 consolidation. H1 2026 loss benefited from a HK$11.1M one-off gain on CB modification, HK$5.5M gain on Meerkat disposal and HK$4.9M government AI subsidies; excluding these the adjusted continuing loss was HK$17.6M.

Balance sheet

The company's own gearing deducts HK$48.65M of deposits pledged against other borrowings. FY2025 equity attributable shows a minor inconsistency between the balance sheet (HK$89.1M) and statement of changes in equity (HK$89.2M).

30 June 2026 snapshot: total assets HK$357.8M; cash HK$60.3M (HK$28.2M held in RMB in the PRC); bank and other borrowings HK$103.0M (of which HK$58.1M interest-free other borrowings); CB HK$54.4M (now non-current, due 21 Apr 2028) plus HK$9.5M accrued interest; total equity HK$59.6M; equity attributable HK$123.6M; net current assets HK$31.6M; current ratio 1.20; gearing 0.93x. July 2026 placings added a further HK$65M gross.

Cash flow

The group burns roughly HK$45–55M of operating cash per year on current run-rates and has relied on equity placements (HK$110M gross raised May–July 2026) and borrowings.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Segment revenue (HKD Mn)

Segment revenue (HKD Mn)FY2022FY2023FY2024FY2025

Echartnow revenue (HKD Mn)

606.2943.9869.6472.0

Meerkat Health revenue (HKD Mn)

824.2399.4145.997.9

Entertainment and Media revenue (HKD Mn)

151.00.73.10.2

Total revenue continuing basis (HKD Mn)

1,581.41,344.01,018.5570.1

Segment Margins & Growth (%) and Revenue by Segment (%)

MetricFY2022FY2023FY2024FY2025

Echartnow revenue growth YoY (%)

—55.7-7.9-45.7

Meerkat Health revenue growth YoY (%)

—-51.5-63.5-32.9

Echartnow share of revenue (%)

38.370.285.482.8

Meerkat Health share of revenue (%)

52.129.714.317.2

Entertainment and Media share of revenue (%)

9.50.10.30.04

Results by Segment and Segment Margins & Growth (%)

Segment metric (HKD Mn unless %)FY2022FY2023FY2024FY2025

Echartnow gross profit (HKD Mn)

——336.7161.9

Echartnow gross margin (%)

——38.734.3

Echartnow segment result (HKD Mn)

——-30.8-12.8

Meerkat Health gross profit (HKD Mn)

——19.11.1

Meerkat Health segment result (HKD Mn)

——-6.9-3.8

Entertainment and Media gross profit (HKD Mn)

1.10.73.10.03

Entertainment and Media segment result (HKD Mn)

-122.93.6-85.7-2.8

Total segment result (HKD Mn)

——-123.3-19.4

Revenue by Segment and Segment Margins & Growth (%)

Segment metric (HKD Mn unless %)H1 2025H1 2026

Echartnow revenue (HKD Mn)

241.1220.1

Echartnow gross margin (%)

33.135.0

Echartnow segment result (HKD Mn)

-11.93.3

Entertainment and Media revenue (HKD Mn)

0.20.0

Entertainment and Media segment result (HKD Mn)

1.00.8

Meerkat Health revenue discontinued (HKD Mn)

61.10.1

Meerkat Health result discontinued (HKD Mn)

-2.0-0.3

Income Statement and Margin Analysis (%)

MetricFY2021FY2022FY2023FY2024FY2025

Revenue as originally reported (HKD Mn)

323.81,692.11,344.01,018.5570.1

Revenue continuing ops restated (HKD Mn)

323.81,581.41,344.01,018.5570.1

Revenue growth YoY restated basis (%)

——-15.0-24.2-44.0

Cost of sales (HKD Mn)

———659.6407.1

Gross profit (HKD Mn)

———358.9163.0

Gross margin (%)

———35.228.6

Marketing and selling expenses (HKD Mn)

———352.9156.8

R&D expenses (HKD Mn)

———17.310.4

Administrative expenses (HKD Mn)

———70.451.5

Operating loss derived (HKD Mn)

———-71.3-51.8

Operating margin derived (%)

———-7.0-9.1

Net finance costs (HKD Mn)

———-17.6-19.1

Share of associate results (HKD Mn)

-4.9-4.8-1.6-6.8-3.3

Impairment of associate (HKD Mn)

———-76.10.0

Loss before taxation (HKD Mn)

-141.8-318.1-119.6——

Net loss for the year (HKD Mn)

-141.4-316.6-125.4-177.2-76.3

Net loss attributable to owners (HKD Mn)

———-163.5-66.7

Adjusted non-HKFRS loss (HKD Mn)

———-103.2-73.1

Net margin (%)

-43.7-20.0-9.3-17.4-13.4

Dividend per share (HKD)

———00

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Income Statement and Per-Share Data

MetricH1 2023H1 2024H1 2025H1 2026

Revenue as reported (HKD Mn)

687.7489.4241.3220.1

Gross profit continuing (HKD Mn)

——79.877.0

Loss for the period (HKD Mn)

-57.4-46.2-42.6-5.0

Loss attributable to owners (HKD Mn)

-43.8-41.0-35.0-5.2

Basic loss per share (HK cents)

—-0.30-2.57-0.35

Balance Sheet and Financial Ratios (x)

MetricFY2024FY2025

Total assets (HKD Mn)

—360.5

Cash and cash equivalents (HKD Mn)

34.523.9

Bank and other borrowings (HKD Mn)

75.183.9

Convertible bonds liability (HKD Mn)

115.959.5

Lease liabilities (HKD Mn)

—4.6

Net debt derived (HKD Mn)

156.5124.1

Long-term financial liabilities Yitang (HKD Mn)

—56.1

Total liabilities (HKD Mn)

—332.6

Total equity (HKD Mn)

23.727.9

Equity attributable to owners (HKD Mn)

103.389.2

Non-controlling interests (HKD Mn)

-79.6-61.3

Goodwill (HKD Mn)

—27.2

Intangible assets (HKD Mn)

—0.3

Interest in associate HB Entertainment (HKD Mn)

—100.6

Net current assets (HKD Mn)

2.8-84.1

Current ratio (x)

1.020.69

Gearing company definition (x)

4.92.8

Cash Flow

MetricH1 2025H1 2026

Operating cash flow (HKD Mn)

-28.2-24.7

Capex PP&E and intangibles (HKD Mn)

-0.2-0.1

Free cash flow derived (HKD Mn)

-28.4-24.8

Proceeds from share issuance (HKD Mn)

0.045.0

Net borrowing inflow (HKD Mn)

11.915.7

Dividends paid (HKD Mn)

00

Share buybacks (HKD Mn)

00

Financial Analysis

RatioValueBasis

ROE (attributable)

approx. −69%

−66.7 / avg(103.3, 89.2), derived

ROE (aggregator)

−86.0%

MarketInOut, Aug 2026

ROA (aggregator)

−17.2%

MarketInOut

ROIC (aggregator)

−17.6%

MarketInOut

Current ratio

0.69 (FY2025); 1.20 (30 Jun 2026)

Filings

Debt/equity (aggregator)

1.66

MarketInOut

Net debt / EBITDA

Not meaningful (negative EBITDA)

—

Interest coverage

Not meaningful (negative EBIT)

—

Asset turnover

approx. 1.6x

570.1 / 360.5, derived

Altman Z-score (aggregator)

−6.79

MarketInOut

Piotroski F-score (aggregator)

3/9

MarketInOut

Revenue by geography (HKD Mn)

Revenue by geography (HKD Mn)H1 2025H1 2026

PRC revenue (HKD Mn)

241.3220.1

Hong Kong revenue (HKD Mn)

0.00.0

South Korea revenue (HKD Mn)

0.00.0

Non-current assets by geography (HKD Mn)

Non-current assets by geography (HKD Mn)FY2025H1 2026

PRC non-current assets (HKD Mn)

42.142.5

Hong Kong non-current assets (HKD Mn)

1.71.1

South Korea non-current assets (HKD Mn)

100.699.8

Share Price

Metric2026-07-282026-08-032026-09-282026-10-09

Share price close (HKD)

0.390.520.410.45

Valuation Snapshot

MultipleValueBasis

Market cap

~HK$791M

1,757.15M shares

Enterprise value

~HK$895M

  • borrowings 103.0 + CB 54.4 + leases 7.0 − cash 60.3 (30 Jun 2026; excludes Yitang liability and July cash)

EV / Sales (TTM continuing ~HK$451M)

~2.0x

Derived

P/E

n/m (loss)

—

EV/EBITDA

n/m (negative)

Aggregator −13.1x

P/B (equity attributable HK$123.6M)

~6.4x

Derived

Analyst coverage

0 analysts

Simply Wall St

Analyst Conclusions

Management guidance: No numerical guidance. Management expects Echartnow to stabilise and grow its high-value share, expand RWS/medical-data services and deepen Top-20 client relationships; robotics is to be scaled through property-manager platform agreements. No consensus estimates exist (zero analyst coverage).

Bull case

  1. Echartnow has crossed into segment profitability (H1 2026) with improving gross margin; revenue stabilisation from a lower, higher-quality base could produce group breakeven in 2027.

  2. AIROBO has signed blue-chip property managers (Longfor, Greentown, A-Living, Central China, Excellence) within weeks; a platform model with recurring fees could command a technology multiple.

  3. Balance sheet repaired: CB pushed to 2028, cash raised HK$110M in 2026, current ratio >1.

Bear case

  1. Revenue has shrunk ~64% from the FY2022 peak; one client is ~42% of revenue; the core market faces regulatory budget compression.

  2. Robotics is pre-revenue, relies on a newly founded partner, and press reports describe the platform as early-stage; the rename resembles prior narrative pivots that did not create value.

  3. Sponsor exits (Hony, Tencent), a vacant chair, pledged core assets and serial dilution at HK$0.40 suggest limited institutional support; 2028 CB and Yitang obligations loom.

Catalysts / monitorables (next 12 months)

  • Effective date of AIROBO Platform Group name and new short name.

  • First disclosed AIROBO revenue, contract values and robot fleet metrics (FY2026 results, ~March 2027).

  • Appointment of a new chairman and any board refresh.

  • Echartnow H2 2026 revenue trend and Customer B concentration.

  • Further placements/dilution; any asset injection related to AIROBO's controller.

  • Progress (or not) toward a Suzhou Yizhinuo IPO versus the Yitang repurchase clause.

  • HB Entertainment pipeline and potential monetisation of the 30.77% stake.

Analyst verdict. Hony Media Group is not a media company and, on current evidence, not yet a robotics company. It is a small, cash-consuming PRC pharma-marketing services business — Echartnow — wrapped in a Hong Kong listed shell that has been repeatedly re-purposed by successive sponsors. Echartnow deserves credit: after a brutal FY2025 in which revenue halved under China's pharma compliance crackdown, management cut costs aggressively, lifted the share of high-value compliance work above half of revenue, and delivered a small segment profit in H1 2026. That is real operating progress, and the policy direction toward traceable, digital commercial operations is a genuine structural tailwind. However, the business remains sub-scale, highly concentrated in one customer, and still shrinking at the top line.

The 2026 governance sequence is the decisive analytical fact. Within eight weeks, Hony Capital's chairman resigned, Tencent sold out, control reverted to long-standing shareholder-director Yuen Hoi Po, a robotics JV was formed with a months-old partner, and a rename to AIROBO Platform Group was proposed and approved. Equity was raised at HK$0.40 while the stock subsequently traded higher on the robotics narrative. Investors should treat AIROBO as an option with unquantified economics: there is no disclosed revenue, contract value, unit economics or patent portfolio, and the platform's capability claims largely originate from the partner and press releases.

Valuation at roughly 2x EV/Sales and over 6x book embeds substantial robotics optionality on top of a marginally profitable services segment. Absent disclosed robotics revenue and a credible independent chairman, risk-reward skews negative for fundamental investors, with high volatility suited only to speculative positioning. The FY2026 annual results will be the first real test of whether the AIROBO narrative converts into reportable numbers. Stance: Speculative / High Risk — monitor, do not underwrite on narrative alone.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameRoleTenureBackgroundAge

YUEN Hoi Po (袁海波)

Executive Director & CEO (from 18 Jun 2026); chairs Executive and Corporate Governance Committees; member Remuneration & Nomination Committees; interim chair functions

Long-standing director (aggregator shows ~15 years); CEO pre-Apr 2024, President Apr 2024–Jun 2026

Bachelor's, Heilongjiang University; trade, real estate, tourism and services since 1990; INED of Minsheng International (938.HK) Nov 2018–Jan 2025; sole shareholder/director of substantial shareholder Smart Concept Enterprise Limited

63

CHENG Wu (程武)

Executive Director (CEO Apr 2024–Jun 2026; earlier Vice-Chairman)

ED since c.2016 Tencent era

Joined Tencent Nov 2009; Group VP; chairman Tencent Animation & Comic and Tencent Literature; CEO Tencent Pictures; former CEO China Literature; NED Maoyan Entertainment (Jun 2020–Nov 2022)

b.1975

YUEN Kin

INED; chairs Audit and Remuneration Committees

9 years

——

WANG Song Song

INED; Audit, Remuneration, Nomination member

———

PAN Min

INED; chairs Nomination Committee; Audit member

———

Chairman

Vacant since 18 Jun 2026

—

Company searching for candidate

—

Board & Management Changes

DateChangeContext

24 Apr 2024

Zhao John Huan appointed NED & Chairman; Cheng Wu appointed CEO; Yuen Hoi Po to President

Linked to Hony Capital's HK$120M CB investment

3 Nov 2025

INED Chu Yuguo resigned

Committee reshuffle

18 Jun 2026

Zhao John Huan resigned (other work arrangements); Cheng Wu resigned as CEO (personal work arrangements); Yuen Hoi Po redesignated CEO

Chair vacant; CG Code C.2.1 deviation disclosed

Major Shareholders

HolderShares (M)Approx. %Basis / caveat

Yuen Hoi Po (personal 45.9M + Smart Concept Enterprise 193.8M)

239.713.6

18 Jun 2026 announcement; % derived

Tencent Holdings (historical controlling shareholder)

Sold ~202M (~11.5%) on 7 Aug 2026

Reported as exit

etnet; residual not confirmed

Hony Capital vehicle (CB holder)

59.8 (conversion shares) + 60.5 potential on conversion

3.4 (6.6 fully converted)

Interim Note 28; % derived

Liu Dongwei & Wang Xueting (May 2026 subscribers)

112.5 combined (split n/d)

6.4

Interim Note 27

July 2026 independent subscribers (several)

162.5 combined

9.2

Interim Note 32

Competitive Landscape

Competitors by Segment

SegmentNamed competitorsPositioning vs. Hony

Pharma digital marketing / physician platforms (Echartnow)

MedLive Technology (2192.HK); DXY (丁香園, private); Medlinker (private); Yidu Tech (2158.HK, RWD/data); Ping An Health (1833.HK); JD Health (6618.HK) and Alibaba Health (0241.HK) in adjacent pharma services; traditional CSOs

Echartnow is sub-scale versus MedLive/DXY in physician reach (~90k verified doctors) but differentiates on compliance-wrapped execution and regional government platforms

Robotics operations in property management (AIROBO)

Onewo (2602.HK) robotics services; Country Garden Services (6098.HK) robotics; UBTech (9880.HK); robot OEMs with own fleet software — Pudu, Keenon, Gausium, Youibot (03231.HK, also a partner)

AIROBO is hardware-agnostic and early-stage; OEMs and large property managers can build in-house

Content / Korean & Chinese drama (E&M)

Studio Dragon (KOSDAQ: 253450); SLL; CJ ENM; Huanxi Media (1003.HK); Maoyan (1896.HK); Alibaba Pictures (1060.HK); Huayi Brothers (300027.SZ)

Hony has only a minority associate stake; no scale

Competitor Detail

MetricHony Media FY2025

Revenue

HK$570.1M

Revenue growth

−44%

Gross margin

28.6%

R&D intensity

1.8%

Recent Developments

--

Company Snapshot

114

Employees

$101M

Market Cap

2002

Founded

/F, Hong Kong

Headquarters

SWOT Analysis

Strengths

  • Echartnow turned to segment profit of HK$3.3M in H1 2026 from a HK$11.9M loss (2026 Interim).
  • Echartnow gross margin improved to 35.0% in H1 2026 from 33.1% (2026 Interim).
  • Client base expanded to 449 pharma companies at 30 Jun 2026 (+8.2% vs end-2025) and 415 at end-2025 (+26.5%) (Interim; FY2025 AR).
  • High-value projects reached 36% of FY2025 Echartnow revenue (+200% YoY) and >50% in Q4 2025 (FY2025 AR).
  • Liquidity repaired: cash HK$60.3M at 30 Jun 2026 (2.5x Dec 2025), plus HK$65M July raise; current ratio 1.20 (Interim).
  • Government endorsements: Shaanxi platform designation; two AI applications on Suzhou list; Xi'an committee chair (FY2025 AR; Interim).

Weaknesses

  • Revenue fell 44% in FY2025 and a further 9% in H1 2026 (FY2025 AR; Interim).
  • Persistent net losses every year FY2021–FY2025, cumulative ~HK$837M (results announcements).
  • Single-customer concentration: Customer B = HK$92.7M, ~42% of H1 2026 revenue (Interim Note 5c).
  • Thin equity: total equity HK$27.9M at end-2025; NCI deficit −HK$64.0M at Jun 2026 (FY2025 AR; Interim).
  • Key assets pledged to CB holder, incl. 30.77% HB Entertainment and 46.18% of Suzhou Yizhinuo (Interim Note 28).
  • Very high staff turnover — 45.96% in FY2025, 54.78% for staff aged ≤35 (FY2025 ESG Report).

Opportunities

  • Compliance regime requires standardised, traceable digital operating systems — structural demand for Echartnow (FY2025 AR).
  • RWD/RWS services ("Wei Jian Zhi Yan" pilot) open higher-margin data revenue (Interim).
  • AIROBO anchor agreements with Longfor (5 years, ~360M sqm managed) and Greentown (3 years) (Aug 2026 announcements).
  • AIROBO Platform 1.0 already deployed in Greentown projects with dozens of robot models adapted (28 Aug 2026 announcement).
  • Government AI subsidies (HK$4.9M H1 2026) offset R&D cost (Interim).
  • Possible Echartnow IPO under the Yitang Qualified-IPO clause could crystallise value (Interim Note 26).

Threats

  • Yitang repurchase obligation (cost + 10% p.a.) if no Qualified IPO within 5 years of 2023 — liability already HK$60.6M (Interim Note 26).
  • CB principal HK$60M plus accrued interest due 21 Apr 2028 (Interim Note 28).
  • Further pharma budget cuts under anti-bribery guidelines (FY2025 AR).
  • Sponsor exits — Hony chairman resigned Jun 2026; Tencent sold ~11.5% Aug 2026 (HKEX; etnet).
  • Continued equity dilution: 275M new shares issued May–Jul 2026 at HK$0.40 (~18.5% of pre-placing capital) (Interim).
  • Narrative-driven stock volatility and potential regulatory scrutiny of rapid pivots/name changes (price +51% intraday 7 Aug 2026; −7.9% 28 Sep 2026).

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
H1 2025Over 60% of leading pharma cut non-core digital-marketing budgets; Echartnow restructuresRevenue shock; cost reset
May 2025Yitang adds RMB2.5M to Suzhou YizhinuoExtends repurchase-clause liability
26 Jun 2025AGM; all resolutions passRoutine
2025New Nomination & Corporate Governance Committee arrangements; HK office address changeGovernance
28 Aug 2025H1 2025 results: loss HK$42.6MWeak half
3 Nov 2025INED Chu Yuguo resignsBoard thinning
17–28 Nov 2025Hony converts HK$60M CB at HK$1.003Hony becomes shareholder
9–11 Dec 2025EGM approves 10:1 consolidation; effective 11 DecCapital structure
22 Jan 2026CB extension deed signedLiquidity relief
30 Jan 2026Meerkat Health sold for HK$1Portfolio simplification
Jan 2026HB Entertainment's "Recipe for Love" airs (KBS 2TV), peak 18.0% ratingAssociate profit
19 Mar 2026Extension deed effective (maturity 21 Apr 2028)Removes near-term default risk
26–31 Mar 2026FY2025 results: revenue −44%, loss −57%Turnaround in losses
21 Apr 2026FY2025 Annual Report publishedDisclosure
13–14 May 2026Share price swings (+20% then −20%)Volatility
19 May 2026AGMRoutine
26 May 2026Subscription for 137.5M shares at HK$0.40 (17.5% discount)Dilutive funding for staff/rent/working capital
15 Jun 2026Agreement I completed (HK$45M); Agreement II terminatedPartial funding
18 Jun 2026Zhao resigns as Chairman; Cheng Wu resigns CEO; Yuen Hoi Po CEOSponsor exit; control reverts
3–6 Jul 2026162.5M share subscription at HK$0.40 (HK$65M)Echartnow AI platform & R&D
Jul 2026Investment properties sold (RMB7.2M); CB conversion price adjusted to HK$0.9925Housekeeping
7 Aug 2026Tencent sells ~202M shares (~11.5%) off-market for ~HK$50.6M; stock +51% intradayStrategic shareholder exit
12 Aug 2026AIROBO robotics JV announcedStrategic pivot
14 Aug 2026Profit warning: H1 loss to narrow to below HK$10MPositive alert
17 Aug 2026Longfor 5-year robotics platform agreementAnchor client
19 Aug 2026Name change to AIROBO Platform Group proposed; Central China/Excellence/Junfa agreementsRebrand
25 Aug 2026Greentown 3-year agreement; Global Unicorn Summit forum; robot allianceEcosystem
27 Aug 2026H1 2026 results: loss HK$5.0M (−88%); Echartnow segment profitOperating improvement
28 Aug 2026AIROBO Platform 1.0 launchedProduct milestone
2 Sep 2026CAS Institute of Mechanics joint labR&D
4 Sep 2026A-Living robot service agreementPipeline
7 Sep 2026EGM notice for name changeCorporate action
22 Sep 2026Strategic cooperation with Youibot and four othersSupply ecosystem
28 Sep 2026Shares fall ~7.9% to HK$0.41Volatility
29 Sep 2026EGM approves name change (99.99%)Pending effectiveness
9 Oct 2026Shares close HK$0.450 (+8.4%)Latest price

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

6 charts
Income Statement: Revenue & Gross Profit: Revenue as originally reported rose from HKD 323.8 Mn in FY2021 to HKD 570.1 Mn in FY2025.
Hony Media Group — Income Statement: Revenue & Gross Profit
Series (HKD Mn)FY2021FY2022FY2023FY2024FY2025
Revenue as originally reported323.81,692.11,3441,018.5570.1
Revenue continuing ops restated323.81,581.41,3441,018.5570.1
Cost of sales———659.6407.1
Gross profit———358.9163

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.